Jililing powder is processed into veterinary tablets by high-shear wet granulation when the as-received material shows a Carr index above 30 and a particle-size D90 above 125 µm. In a 600 L high-shear granulator with a 1:3 impeller-to-chopper speed ratio, the active is pre-blended for 4 min at 120 rpm before binder addition. A 4.0% w/w hydroxypropyl cellulose solution in purified water provides granulate with a final loss on drying between 1.2% w/w and 1.8% w/w; higher residual moisture above 2.0% w/w has caused picking and elevated ejection force on 45-station rotary tablet presses during consecutive batches. Croscarmellose sodium is split at 3.0% w/w intragranular and 1.0% w/w extragranular, while sodium stearyl fumarate is added at 1.0% w/w, yielding a compression mix with bulk density 0.52–0.58 g/cm³. Tablets are compressed to 60–80 N hardness using 9.5 mm round concave tooling; friability remains below 0.5% after 4 min at 25 rpm under USP 1216. Dissolution acceptance follows USP 711 Apparatus II at 50 rpm in 900 mL of pH 6.8 phosphate buffer, with a Q value of 70% at 45 min. Content uniformity under USP 905 must not exceed an acceptance value of 15.0; routine 100 mg label claim batches maintain an AV below 7.0 when granulate particle-size D50 is controlled between 80 µm and 150 µm. Direct compression is excluded when lactose monohydrate flow falls below 18 g/s through a 15 mm orifice or when API loading exceeds 30% w/w, because segregation potential exceeds blend uniformity capability.

Which Pre-Filtration Loading Limits Apply to Jililing in Aqueous Injectable Solutions Above pH 6.0?

In aqueous injectable formulation, Jililing is processed as a sterile solution at target concentrations from 10 mg/mL to 100 mg/mL. For vehicles above pH 6.0, hydrolytic degradation can accelerate, and screening under VICH GL3 forced-degradation conditions is a prerequisite before formula lock. Solubility in water for injection is determined at 20°C and 37°C; if saturation at 20°C is below the target concentration, propylene glycol may be added at 20–40% v/v with benzyl alcohol at 1.5% v/v, but final osmolality is maintained between 280 mOsmol/kg and 340 mOsmol/kg for small-volume parenterals. The bulk solution is pre-filtered through 0.45 µm polyether sulfone membrane and then through a 0.22 µm sterilising-grade membrane at a differential pressure not exceeding 2.0 bar; membrane loading above 50 L/m² without prefiltration has produced premature plugging at 100 mg/mL. Under USP 788, light obscuration counts for particles ≥ 10 µm must not exceed 6000 per container and for particles ≥ 25 µm must not exceed 600 per container. Endotoxin testing follows USP 85 with a limit calculated as K/M, where K is 5 EU/kg for parenteral administration and M is the maximum bolus dose per kilogram body weight; routine API lots demonstrate below 0.05 EU/mg. Terminal steam sterilisation at 121°C for 15 min is acceptable only when forced-degradation data show assay loss ≤ 2.0% and total impurities ≤ 0.2%; if published data for this specific veterinary API in acid-buffered vehicles are limited, aseptic filtration under ISO 5 laminar flow is mandatory. A nitrogen overlay of 0.5 bar in the header tank is used for oxygen-sensitive Jililing solutions, and dissolved oxygen is held below 2.0 mg/L. The container system is Type I borosilicate glass under USP 660 with butyl rubber stoppers, and headspace oxygen is monitored below 5% v/v by laser spectroscopy.

Direct capsule filling of Jililing powder on a GKF 2400-class dosator machine requires that the tapped density of the lubricated blend be maintained between 0.48 g/cm³ and 0.56 g/cm³. Directly filled hard gelatin capsules at API content below 25% w/w in a lactose monohydrate-based blend are feasible only when the mixture passes through a 600 µm sieve and the angle of repose remains below 38°. Magnesium stearate is limited to 0.5% w/w and is sieved co-blended for 3 min on a diffusion mixer at 12 rpm to prevent over-lubrication, which delays disintegration beyond 15 min in water at 37°C. Size 1 capsules are filled with a target weight of 250 mg and a maximum weight variation of ±7.5%; during an 8 h run, weight drift beyond ±2.0% relative to initial fill indicates powder bed densification and requires hopper level control to ±5 cm. The finished capsule is tested by USP 905 for content uniformity and by USP 711 Apparatus I at 100 rpm in 900 mL of 0.1 N HCl with a Q of 75% at 30 min. When empty capsule shell moisture content is outside 13.0–16.0% w/w, brittle fracture occurs on the ejector pin; therefore shells are stored at 20–25°C and 45–50% RH for 48 h before filling. Jililing API is pre-dried at 40°C to loss on drying ≤ 1.0% w/w when water activity measured by dew-point instrument exceeds 0.60.

When Powder Flowability Falls Below 0.35 g/s Through a 10-mm Orifice, Granulation Becomes Mandatory for Sachet Filling

Dry powder for oral solution in sachets containing Jililing at 50 mg to 500 mg per unit is granulated after flow evaluation by a ring shear tester. A flow function coefficient below 2.5 or an orifice discharge rate below 0.35 g/s from a 10 mm diameter polished stainless steel funnel is the process trigger. In a top-spray fluid bed granulator with 120 kg working capacity and inlet air temperature 55–65°C, a 6.0% w/w povidone K-30 binder is sprayed at 180 g/min, while product temperature is kept at 28–32°C and final moisture by halogen drying is 1.0–1.5% w/w. Granule size is controlled by sieve fraction: at least 85% of mass should pass through 500 µm and be retained on 125 µm. Over-granulation above 700 µm slows reconstitution, while under-granulation below 90 µm increases dusting and sachet seal contamination. Sachet filling on vertical form-fill-seal equipment with 10-lane volumetric dosing requires bulk density variation not exceeding ±5.0% between hopper top and bottom samples. Fill weight RSD is held below 2.0% for a 1.0 g target fill. The laminate structure is PET 12 µm / Al 9 µm / PE 50 µm with moisture vapour transmission rate below 0.5 g/m²/24 h at 38°C and 90% RH. Reconstitution time in 100 mL water at 20°C is ≤ 60 s; the resulting solution passes through a 250 µm sieve with residue ≤ 5.0 mg.

Medicated Feed Premix Homogeneity Acceptance Under VICH GL10 and ISO 6497

For medicated feed premix production, Jililing powder is diluted to 1.0% w/w, 5.0% w/w, or 10.0% w/w active content using ground limestone carrier with moisture ≤ 1.0% w/w and particle-size D50 150–200 µm. Overdosing above 10.0% w/w is not recommended for standard ribbon blender geometries because decreasing carryover and segregation controllability exceeds the validated mixing capability. A double-ribbon mixer of 500 kg gross capacity with 60% fill volume reached a coefficient of variation of 3.4% after 20 min at 12 rpm, whereas a vertical screw mixer of identical capacity required 30 min to fall below 5.0% CV. Stratified sampling follows ISO 6497, with 10 samples per batch collected from top, middle, and bottom discharge zones. Assay acceptance for single samples is 90.0–110.0% of label claim and full-batch CV ≤ 5.0%. Carryover after a 5.0% w/w Jililing premix batch into a subsequent non-medicated feed must not exceed 0.1% w/w of the intended dose; cleaning validation swab limits are calculated under 21 CFR 225.30 and 21 CFR 225.65. Ribbon mixer end-plate and discharge gate residual accumulation has been the primary cross-contamination source; therefore sealed end-plate design and wash-in-place at 45°C with 0.5% w/w sodium carbonate solution are specified. The final premix is packed in 25 kg multi-wall paper bags with an inner polyethylene liner of 80 µm thickness; storage is maintained at ≤ 25°C and ≤ 60% RH. Moisture increase above 2.0% w/w during storage activates caking and assay heterogeneity after 90 days.

Oral Drench Solutions Demand Viscosity Below 100 mPa·s and pH 3.5–6.0 for Dosing Pump Accuracy

When a dosing pump must deliver a Jililing oral drench at volumes below 5 mL, viscosity and pH are controlled as critical process parameters. Jililing is dissolved or suspended in oral drench vehicles at 10 mg/mL to 200 mg/mL. For true solutions, a vehicle containing 20–30% v/v propylene glycol, 0.1% w/v sodium benzoate, and purified water adjusted to pH 4.0–5.5 maintains chemical stability when the API is acid-labile below pH 3.0 and base-labile above pH 7.0. Viscosity measured with a rotational viscometer at 20°C and 100 s⁻¹ shear rate is kept below 100 mPa·s; higher viscosity produces dosing pump calibration drift exceeding ±5.0% on peristaltic dosing guns. Antimicrobial effectiveness is verified by USP 51 criteria for category 3 products; bacterial count limits comply with USP 1111 for oral liquid preparations, with total aerobic count not exceeding 10³ CFU/g and combined yeasts and moulds not exceeding 10² CFU/g. The solution is filtered through a 0.45 µm membrane and filled into amber polyethylene terephthalate bottles with 28 mm child-resistant closures. Light transmission below 10% between 350 nm and 450 nm is required when photostability testing under VICH GL5 shows assay loss of 2.0% or greater. Lyophilization is not permitted for this dosage form because reconstitution introduces dosing errors; therefore the oral liquid formulation is limited to systems with 24-month real-time stability data in the specified bottle-closure system.